Though Bacher et al. only report prognostic significance in normal karyotype, FLT3-unmutated, and NRAS-mutated AML (an improved EFS in the NRAS-mutant group compared to NRAS wild-type, p = 0.06) but otherwise report no significant prognostic association, Kiyoi et al. found that CR rates after initial induction were lower in the wild-type FLT3/mutant NRAS group (52%) than in the wild-type FLT3/wild-type NRAS group (79.7%), with p = 0.005 [17,187]. The gene discussed is NRAS; the disease is acute myeloid leukemia.